3 results
Approved WMOCompleted
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
Approved WMORecruiting
The aim is to see whether intradialytic parenteral nutrition is an efective treatment against the loss of muscle mass
Approved WMORecruiting
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…